MaryStanleyBeattieMD

PubMed

• 70 citations
  Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
  Razelle Kurzrock, Daniel W. Bowles, Hyunseok Kang, Funda Meric-Bernstam, John D. Hainsworth, David R. Spigel, Ron Bose, H. A. Burris, Christopher Sweeney, Michael S. B...> ;Annals of Oncology. 2020 Mar 1
• Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
  Sandra M. Swain, Andreas Schneeweiss, L. Gianni, Jianjiong Gao, A Stein, M Waldron-Lynch, Sarah Heeson, Michael S. Beattie, Bongin Yoo, J. Cortés, J. Baselga> ;Annals of Oncology. 2019 Aug 1
• 282 citations
  Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket st...
  , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2019 Apr 1
• 2 citations
  Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
  S M Swain, A Schneeweiss, L Gianni, J J Gao, A Stein, M Waldron-Lynch, S Heeson, M S Beattie, B Yoo, J Cortes, J Baselga> ;Annals of Oncology. 2018 Jul 1
• Reply to J.J. Tao et al
  John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein,...> ;Journal of Clinical Oncology. 2018 Jun 1
• 291 citations
  Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study
  John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein,...> ;Journal of Clinical Oncology. 2018 Jan 10
• 10 citations
  Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial
  David Miles, Yunjoo Im, A. Fung, Bongin Yoo, Adam Knott, Sarah Heeson, Michael S. Beattie, Sandra M. Swain> ;Annals of Oncology. 2017 Nov 1
• 3 citations
  Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
  S M Swain, A Schneeweiss, L Gianni, J J Gao, A Stein, M Waldron-Lynch, S Heeson, M S Beattie, B Yoo, J Cortes, J Baselga> ;Annals of Oncology. 2017 Apr 1
• 2 citations
  NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer
  Eli Korner, Anne Morris, Isabel E. Allen, Sara A. Hurvitz, Mary Beattie, Bindu Kalesan> ;Systematic Reviews. 2015 Oct 1
• 8 citations
  Characteristics and temporal trends in patient registries: focus on the life sciences industry, 1981-2012.
  Karin Travers, Rachel H. Sallum, Meghan D. Burns, Charles E. Barr, Mary Beattie, CL Pashos, Bryan R Luce> ;Pharmacoepidemiology and Drug Safety. 2015 Apr 1
• 23 citations
  The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic b...
  Debasish Tripathy, Hope S. Rugo, Peter A. Kaufman, Sandra M. Swain, Joyce O'Shaughnessy, Mohammad Jahanzeb, Ginny Mason, Mary Beattie, Bongin Yoo, Catherine Lai, Antho...> ;BMC Cancer. 2014 May 2
• 96 citations
  DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers
  Ana Osorio, Roger L. Milne, Karoline Kuchenbaecker, Tereza Vaclova, Guillermo Pita, Rosario Alonso, Paolo Peterlongo, Ignacio Blanco, Miguel de la Hoya, Mercedes Durán...> ;Plos Genetics. 2014 Apr 3
• 3 citations
  Genetic counseling, cancer screening, breast cancer characteristics, and general health among a diverse population of BRCA genetic testers.
  Mary S. Beattie, Kelli Copeland, Julia Fehniger, Eleanor Cheung, Galen Joseph, Robin Lee, Judith Luce> ;Journal of Health Care for the Poor and Underserved. 2013 Aug 1
• 66 citations
  Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers.
  Julia Fehniger, Feng Lin, Mary S. Beattie, Galen Joseph, Celia P. Kaplan> ;Journal of Genetic Counseling. 2013 May 12
• 329 citations
  Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
  Fergus J. Couch, Xianshu Wang, Lesley McGuffog, Andy C. H. Lee, Curtis Olswold, Karoline Kuchenbaecker, Penny Soucy, Zachary S. Fredericksen, Daniel Barrowdale, Joe De...> ;Plos Genetics. 2013 Mar 27
• 91 citations
  Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non–clinic‐based sample of women in northern California
  Wayne T. Lin, Mary S. Beattie, Lee-may Chen, Kutluk Oktay, Sybil L. Crawford, Ellen B. Gold, Marcelle I. Cedars, Mitchell P. Rosen> ;Cancer. 2013 May 1
• 23 citations
  Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
  Gabriel N. Mannis, Julia Fehniger, Jennifer S. Creasman, Vanessa L. Jacoby, Mary S. Beattie> ;JAMA Internal Medicine. 2013 Jan 28
• 114 citations
  Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genet...
  Jeffrey N. Weitzel, Jessica Clague, Arelis E. Martir-Negron, Raquel Ogaz, Josef Herzog, Charité Ricker, Chelsy R. Jungbluth, Cheryl Cina, Paul Duncan, Gary Unzeitig, J...> ;Journal of Clinical Oncology. 2013 Jan 10
• 2 citations
  Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers
  Kristen N. Stevens, Xianshu Wang, Zachary S. Fredericksen, Vernon S. Pankratz, Mark H. Greene, Irene L. Andrulis, Mads Thomassen, Maria A. Caligo, Katherine L. Nathans...> ;Breast Cancer Research and Treatment. 2012 Sep 26
• 17 citations
  A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers
  Yuan C. Ding, Lesley McGuffog, Sue Healey, Eitan Friedman, Yael Laitman, Shani Paluch Shimon, Bella Kaufman, Annelie Liljegren, Annika Lindblom, Håkan Olsson, Ulf Kris...> ;Cancer Epidemiology, Biomarkers & Prevention. 2012 Jun 22
• 29 citations
  A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome.
  Ani Kardashian, Julia Fehniger, Jennifer M. Creasman, Eleanor Cheung, Mary S. Beattie> ;Hereditary Cancer in Clinical Practice. 2012 Apr 12
• 37 citations
  Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
  Fergus J. Couch, Mia M. Gaudet, Antonis C. Antoniou, Susan J. Ramus, Karoline Kuchenbaecker, Penny Soucy, Jonathan Beesley, Xiaoqing Chen, Xianshu Wang, Tomas Kirchhof...> ;Cancer Epidemiology, Biomarkers & Prevention. 2012 Apr 1
• 32 citations
  Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
  Susan J. Ramus, Antonis C. Antoniou, Karoline Kuchenbaecker, Penny Soucy, Jonathan Beesley, Xiaoqing Chen, Lesley McGuffog, Olga M. Sinilnikova, Sue Healey, Daniel Bar...> ;Human Mutation. 2012 Apr 1
• 91 citations
  Clinical and biomarker predictors of side effects from tamoxifen
  Wendy Lorizio, Alan H.B. Wu, Mary S. Beattie, Hope S. Rugo, Simone Tchu, Karla Kerlikowske, Elad Ziv> ;Breast Cancer Research and Treatment. 2012 Apr 1
• 71 citations
  Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
  Antonis C. Antoniou, Karoline Kuchenbaecker, Penny Soucy, Jonathan Beesley, Xiaoqing Chen, Lesley McGuffog, Andrew Lee, Daniel Barrowdale, Sue Healey, Olga M. Sinilnik...> ;Breast Cancer Research. 2012 Feb 20
• Join now to see all